CIP2A is associated with multidrug resistance in cervical adenocarcinoma by a P-glycoprotein pathway

• DOI: 10.1007/s13277-015-4032-8
• Publication Date: 2015-09-24T07:10:42Z
• Authors: Juan Liu; Meng Wang; Xiaoli Zhang; Qingwei Wang; Mei Qi; Jing Hu; Zhiqiang Zhou; Chunyan Zhang; Weifang Zhang; Weiming Zhao; Xiao Wang
• Keywords: HeLa; P-glycoprotein

Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a recently identified oncoprotein. Here, we investigated its role in the formation multidrug resistance (MDR) cervical adenocarcinoma vitro and vivo. MTT assay showed that knockdown CIP2A expression increased drug sensitivity HeLa Dox-resistant cells (HeLa-Dox) to doxorubicin, cisplatin, paclitaxel significantly, while overexpression decreased chemo-drugs dramatically. When treated with different chemotherapeutics, P-glycoprotein (P-gp) levels were simultaneously. In accordance it, or inhibited P-gp transcription level separately. The effects on was achieved partly through regulation factor E2F1. Moreover, interference could decrease activity elucidated by Rhodamine 123 (Rh123) efflux HeLa/Dox cells. vivo level, confocal microscopy data demonstrated strong co-localization cells, significantly associated tissues. Thus, involved regulating upon chemotherapy enhancing may be an attractive target anticancer strategies improve effect adenocarcinoma.